Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2022—Dr Reau

Source: Clinical Impact of New Viral Hepatitis Data From AASLD 2022*
November 4-8, 2022; Washington, DC
Listen to expert insights on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.
Nancy Reau, MD
Released: December 8, 2022

Information on this Educational Activity

Faculty

Nancy Reau, MD

Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD: consultant/advisor: AbbVie, Antios, Arbutus, Gilead Sciences, Intercept, Salix; researcher: AbbVie, Gilead Sciences, Intercept.

Program Medium

This program has been made available online.

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings